Rehmann Capital Advisory Group’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$286K Hold
1,693
0.01% 564
2025
Q4
$286K Sell
1,693
-1
-0.1% -$162 0.01% 546
2025
Q3
$245K Hold
1,694
0.01% 564
2025
Q2
$214K Sell
1,694
-296
-15% -$36.3K 0.01% 566
2025
Q1
$255K Buy
1,990
+1
+0.1% +$136 0.02% 524
2024
Q4
$263K Sell
1,989
-473
-19% -$66.5K 0.02% 507
2024
Q3
$359K Sell
2,462
-66
-3% -$9.55K 0.02% 419
2024
Q2
$347K Buy
+2,528
New +$337K 0.02% 412
2022
Q1
Sell
-2,207
Closed -$337K 553
2021
Q4
$337K Sell
2,207
-61
-3% -$9.44K 0.03% 411
2021
Q3
$367K Sell
2,268
-2,757
-55% -$464K 0.03% 390
2021
Q2
$828K Buy
5,025
+2,168
+76% +$334K 0.08% 215
2021
Q1
$430K Buy
2,857
+62
+2% +$9.85K 0.04% 325
2020
Q4
$423K Buy
2,795
+593
+27% +$84.7K 0.05% 302
2020
Q3
$298K Buy
2,202
+31
+1% +$4.21K 0.04% 325
2020
Q2
$297K Buy
+2,171
New +$277K 0.04% 323
2019
Q3
Sell
-2,450
Closed -$267K 1860
2019
Q2
$267K Buy
2,450
+970
+66% +$103K 0.03% 377
2019
Q1
$166K Buy
1,480
+602
+69% +$66K 0.02% 456
2018
Q4
$84.7K Sell
878
-988
-53% -$105K 0.01% 446
2018
Q3
$228K Sell
1,866
-332
-15% -$39.1K 0.03% 370
2018
Q2
$241K Buy
2,198
+353
+19% +$37.8K 0.04% 328
2018
Q1
$197K Buy
+1,845
New +$205K 0.03% 371
2017
Q2
Sell
-2,451
Closed -$240K 393
2017
Q1
$240K Sell
2,451
-102
-4% -$9.77K 0.04% 330
2016
Q4
$226K Buy
+2,553
New +$232K 0.04% 342
2015
Q3
Sell
-1,788
Closed -$220K 351
2015
Q2
$220K Sell
1,788
-567
-24% -$67.9K 0.05% 293
2015
Q1
$269K Buy
2,355
+138
+6% +$15.2K 0.06% 254
2014
Q4
$224K Sell
2,217
-534
-19% -$51.9K 0.05% 294
2014
Q3
$251K Sell
2,751
-96
-3% -$8.43K 0.06% 266
2014
Q2
$244K Buy
+2,847
New +$224K 0.06% 275
2014
Q1
Sell
-2,784
Closed -$211K 332
2013
Q4
$211K Sell
2,784
-1,212
-30% -$86K 0.06% 271
2013
Q3
$279K Buy
+3,996
New +$262K 0.09% 199

Other funds holding IBB

Rehmann Capital Advisory Group's IBB Position: Q1 2026 in Review

Rehmann Capital Advisory Group held its iShares Biotechnology ETF (IBB) position steady in Q1 2026 at 1,693 shares worth $286K. The position accounts for 0.01% of the portfolio, ranked #564.

Rehmann Capital Advisory Group first reported a position in IBB in Q3 2013 and has held it in 30 quarters since. The position peaked at $828K in Q2 2021. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Rehmann Capital Advisory Group held 1,693 shares of iShares Biotechnology ETF worth $286K as of Q1 2026.
  • Rehmann Capital Advisory Group left its iShares Biotechnology ETF share count unchanged in Q1 2026.
  • iShares Biotechnology ETF made up 0.01% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #564 holding.
  • Rehmann Capital Advisory Group first reported a position in iShares Biotechnology ETF in Q3 2013 and has held it in 30 quarters since.
  • Rehmann Capital Advisory Group's iShares Biotechnology ETF position peaked at $828K in Q2 2021.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.